Search Result

Results for "

VEGFR2-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (12) Autophagy (5) Bacterial (1) c-Kit (2) c-Met/HGFR (1) Carbonic Anhydrase (3) Casein Kinase (1) CDK (1) Dihydrofolate reductase (DHFR) (1) EGFR (1) FGFR (1) FLT3 (1) Fungal (1) GSK-3 (1) HDAC (1) Isotope-Labeled Compounds (2) MAP3K (1) Microtubule/Tubulin (2) PDGFR (2) PROTACs (1) Raf (1) RET (1) Tie (1) Topoisomerase (1) VEGFR (26)
By Research Areas:	Cancer (25) Infection (2) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147133

VEGFR2-IN-2

VEGFR Cancer

VEGFR2-IN-2 (compound 6e) is a potent and selective VEGFR2 inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

*VEGFR2-IN-2*	VEGFR	Cancer
VEGFR2-IN-2 (compound 6e) is a potent and selective *VEGFR2* inhibitor with an IC₅₀ of 19.32 nM. VEGFR2-IN-2 can be used for researching

HY-12018

Vatalanib dihydrochloride 10+ Cited Publications PTK787 dihydrochloride; ZK-222584 dihydrochloride; CGP-797870 dihydrochloride	VEGFR Apoptosis	Cancer
Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-147872

VEGFR-2-IN-22	VEGFR Microtubule/Tubulin Apoptosis	Cancer
VEGFR-2-IN-22 (Compound 25) is a dual *VEGFR-2* and β-tubulin polymerization inhibitor with an IC₅₀ of 19.82 nM against VEGFR-2. VEGFR-2-IN-22 induces apoptosis .

HY-155758

hCA/VEGFR-2-IN-2	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-2 (compound 8g) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-2 inhibits VEGFR-2 (IC₅₀=204 nM) and has high binding activity to hCAs, with Kis of 3.6 nM (hCA IX), 16.1 nM (hCA II), 16.7 nM (hCA XII), and 75.3 nM (hCA I), respectively. hCA/VEGFR-2-IN-2 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-149675

VEGFR-2/c-Met-IN-2	VEGFR c-Met/HGFR	Cancer
VEGFR-2/c-Met-IN-2 (compound 3e) is a *VEGFR-2/c-Met* inhibitor, with IC₅₀ values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC₅₀: 3.403 µM) .

HY-151459

VEGFR-2/DHFR-IN-2	VEGFR Bacterial Dihydrofolate reductase (DHFR) Fungal	Infection Cancer
VEGFR-2/DHFR-IN-2 (compound 5b) is an inhibitor of *VEGFR-2* and DHFR with IC₅₀s of 0.623 and 9.085 μM, respectively. VEGFR-2/DHFR-IN-2 exhibits good cytotoxic activities against C26, HepG2, and MCF7 cancer cell lines with IC₅₀ values of 3.59-8.38 μM. VEGFR-2/DHFR-IN-2 can be used for the research of cancer .

HY-12572

*TIE-2/VEGFR-2 kinase-IN-2*	Tie VEGFR	Cancer
TIE-2/VEGFR-2 kinase-IN-2 is a potent dual *VEGFR2* and Tie-2 inhibitor with pIC₅₀ values of 8.61 and 8.56, respectively . TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research .

HY-10203

Vatalanib

10+ Cited Publications

PTK787; ZK-222584; CGP-79787
VEGFR Cancer

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC₅₀ of 37 nM.

Vatalanib 10+ Cited Publications PTK787; ZK-222584; CGP-79787	VEGFR	Cancer
Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of *VEGFR2/KDR* with IC₅₀ of 37 nM.

HY-12018A

Vatalanib hydrochloride PTK787 hydrochloride; ZK-222584 hydrochloride; CGP-797870 hydrochloride	VEGFR Apoptosis	Others
Vatalanib (PTK787; ZK-222584; CGP-797870) hydrochloride is an inhibitor of *VEGFR2/KDR* with an IC₅₀ of 37 nM .

HY-146492

VEGFR-2/BRAF-IN-2	VEGFR Raf Apoptosis	Cancer
VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual *VEGFR-2* and BRAF kinases inhibitor with IC₅₀ values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF ^V600E and BRAF ^WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .

HY-18926

VEGFR2-IN-7

VEGFR2-IN-7 (compound E) is an inhibitor of VEGFR2. VEGFR2-IN-7 can used in study cancers .

VEGFR2-IN-7
VEGFR2-IN-7 (compound E) is an inhibitor of *VEGFR2*. VEGFR2-IN-7 can used in study cancers .

HY-18185

JNJ 17029259	VEGFR	Cancer
JNJ 17029259 is an orally active and selective *VEGF-R2* kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity .

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	MAP3K VEGFR Antibiotic	Infection Inflammation/Immunology
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

HY-155763

*hCA/VEGFR-2-IN-4*	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC₅₀=0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells .

HY-112337

VEGFR-2-IN-44	VEGFR PDGFR	Cancer
VEGFR-2-IN-44 (compound 4b) is a selective VEGF-R2 (Flk-1) inhibitor with an IC₅₀ value of 70 nM. VEGFR-2-IN-44 also inhibits PDGF-Rβ with an IC₅₀ of 920 nM .

HY-146369

PROTAC VEGFR-2 degrader-2	PROTACs VEGFR	Cancer
PROTAC VEGFR-2 degrader-2（PROTAC-4）, a PROTAC VEGFR-2 degrader, exhibits little VEGFR-2 inhibition (IC₅₀> 1 μM) and anti-proliferative activity against EA.hy926 cells (IC₅₀> 100μM) .

HY-10260

Vandetanib Maximum Cited Publications 18 Publications Verification ZD6474	VEGFR Autophagy Apoptosis	Cancer
Vandetanib (D6474) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10260B

Vandetanib hydrochloride ZD6474 hydrochloride	VEGFR Autophagy Apoptosis	Cancer
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10260A

Vandetanib trifluoroacetate ZD6474 trifluoroacetate	VEGFR Autophagy Apoptosis	Cancer
Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of *VEGFR2/KDR* tyrosine kinase activity (IC₅₀=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of *VEGFR3/FLT4* (IC₅₀=110 nM) and *EGFR/HER1* (IC₅₀=500 nM) .

HY-10260S1

Vandetanib-d4	Isotope-Labeled Compounds VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6 ZD6474-d₆	Isotope-Labeled Compounds VEGFR Autophagy Apoptosis	Cancer
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

HY-149630

VEGFR2/HDAC1-IN-1	VEGFR HDAC Apoptosis	Cancer
VEGFR2/HDAC1-IN-1 (compound 13) is a potent *VEGFR-2/HDAC* dual inhibitor, with IC₅₀s of 57.83 nM and 9.82 nM, respectively. VEGFR2/HDAC1-IN-1 arrests the cell cycle at the S and G2 phases, and induces apoptosis in HeLa cells. VEGFR2/HDAC1-IN-1 exhibits anti-angiogenic effect .

HY-112306

Ripretinib DCC-2618	c-Kit PDGFR FLT3 VEGFR Apoptosis	Cancer
Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .

HY-146138

EGFR-IN-57	EGFR VEGFR Casein Kinase Topoisomerase Microtubule/Tubulin Apoptosis	Cancer
EGFR-IN-57 (Compound 25a) is a potent, orally active *EGFR-TK* inhibitor with an IC₅₀ of 0.054 µM. EGFR-IN-57 also inhibits *VEGFR-2, CK2α*, topoisomerase IIβ and tubulin polymerization with IC₅₀ values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis .

HY-155760

*hCA/VEGFR-2-IN-3*	VEGFR Carbonic Anhydrase	Cancer
hCA/VEGFR-2-IN-3 (compound 8j) is an indolinonylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-3 inhibits VEGFR-2 (IC₅₀=358 nM), has high binding activity to hCAs with Ki of 4.2 nM (hCA IX), 22.9 nM (hCA II), 25.1 nM (hCA I), 28.0 nM (hCA XII), respectively. hCA/VEGFR-2-IN-3 has antiproliferative activity against VEGFR-2 overexpressing breast cancer cells .

HY-116116

Tafetinib SIM010603	c-Kit RET VEGFR	Cancer
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), andFms-like tyrosine kinase-3 (FLT3)withIC₅₀values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .

HY-141685

3-Methylthienyl-carbonyl-JNJ-7706621	CDK GSK-3 VEGFR FGFR	Cancer
3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC₅₀s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC₅₀=0.041 μM) and modest potency against CDK4, *VEGF-R2, and FGF-R2* (IC₅₀=0.11, 0.13, 0.22 μM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer .

ATWLPPR Peptide 1 Publications Verification	Peptides	Others
ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

Elpamotide	Peptides	Cancer
Elpamotide is an epitope peptide derived from VEGFR2. Elpamotide induces cytotoxic T lymphocytes (CTLs) to kill VEGFR2-expressing endothelial cells. Elpamotide has potential immunostimulatory and antineoplastic activities. Elpamotide can be used in the research of cancer, such as pancreatic cancer .

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-12686

5Z-7-Oxozeaenol 5+ Cited Publications FR148083; L783279; LL-Z 1640-2	Structural Classification Natural Products Monophenols Microorganisms Classification of Application Fields Source classification Phenols Inflammation/Immunology Disease Research Fields	MAP3K VEGFR Antibiotic
5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and *VEGF-R2, with IC₅₀*s of 8 nM and 52 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-10260S1

Vandetanib-d4
Vandetanib-d₄ is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].

HY-10260S

Vandetanib-d6
Vandetanib-d₆ is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

VEGFR2-IN-2

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products